Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Treatment of Schizophrenia receives notice of intention to grant a European patent

BioLineRx (NASDAQ:BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today that it has received from the European Patent Office a notice of intention to grant a European patent claiming the salt of BL-1020, a first-in-class orally available treatment for schizophrenia.

9 Jul 2012

Oxytocin levels linked to medication dose, symptoms in schizophrenia

Higher doses of second-generation antipsychotics and more severe negative symptoms are associated with lower levels of oxytocin in cerebrospinal fluid among patients with schizophrenia, researchers report.

29 Jun 2012

Mass. nursing homes miss out on federal grant to curb inappropriate sedative use

Nursing Homes In Massachusetts will not get a federal grant to help them drive down use of antipsychotic drugs. In Kansas, officials launched a campaign to encourage reporting of elder abuse.

19 Jun 2012

Health Canada approves Sunovion’s LATUDA NDA to treat schizophrenia

Sunovion Pharmaceuticals Canada Inc. today announced that the New Drug Submission (NDS) for LATUDA (lurasidone HCl), for the treatment of adult patients with acute schizophrenia has been approved by Health Canada.

16 Jun 2012

Hot weather increases death risk in psychosis patients

Hot weather is associated with increased mortality rates among patients with psychosis, dementia, or substance use disorder, UK research shows.

13 Jun 2012

Novel guidelines manage youth maladaptive aggression

Recommendations for the engagement, assessment, treatment, and management of maladaptive aggression in youth have been developed by US experts to improve treatment planning and selection.

6 Jun 2012

Feds announce effort to slash inappropriate use of antipsychotic drugs in nursing homes

An estimated 40 percent of nursing home residents with dementia receive the drugs, which are approved to treat schizophrenia and bipolar disorder.

1 Jun 2012

New guidelines for management of childhood aggression

Mayo Clinic researchers, in collaboration with other research institutions and youth mental health experts, are publishing new guidelines for primary care providers and mental health specialists to manage the common but often complex problem of childhood aggression. The goals include improving diagnosis and care and avoiding inappropriate use of medication.

31 May 2012

Interim data from UCLA and NeuroSigma’s eTNS Phase I trial on PTSD, MDD

Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.

31 May 2012

AssureRx closes $12.5M Series C financing

AssureRx Health, Inc. today announced the closing of a $12.5 million Series C financing. The personalized medicine company, which provides clinically-relevant information to help physicians select the right drug for individual neuropsychiatric patients, will use the funds to increase commercial activities for its two flagship pharmacogenomic products, GeneSightRx Psychotropic and GeneSightRx® ADHD, as well as next generation product development activities.

31 May 2012

Transcranial stimulation technique reduces hallucinations

Transcranial direct-current stimulation is effective for the treatment of auditory hallucinations in patients with schizophrenia, study results show.

30 May 2012

Reid says he will let budget cuts go forward unless there is a concession on revenue

In an interview with POLITICO, (Senate Majority Leader Harry) Reid said he was open to a compromise that would salvage about four-fifths of the Bush-era tax cuts. But absent some concession on revenues, the $110 billion in spending cuts ordered by the debt agreement last August would go into effect. "I am not going to back off the sequestration," Reid said. ... the recent House-passed reconciliation bill, which promises to forestall these very same cuts in January, was the last straw for Reid and helped fortify his position.

25 May 2012

La. panel kills health exchange plan; Kansas enacts another abortion hurdle; Utah official resigns after medical records breach

With a decisive 8-1 vote late Tuesday evening, the Louisiana Senate Finance Committee buried a bill that would have set up a body of elected and appointed officials to craft the exchanges that are an anchor of President Barack Obama's health insurance overhaul. With the death of Senate Bill 744, Louisiana remains one of a handful of states that have refused to set up their own exchanges, with Gov. Bobby Jindal punting the job back to federal government that he accuses of taking over the American health care system

17 May 2012

Reducing off-label antipsychotic use may generate savings with little impact on patient care

Reducing the non-FDA-approved use of antipsychotic drugs may be a way to save money while having little effect on patient care, according to a Penn State College of Medicine study.

16 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

Antidepressives reduce risk of suicides in schizophrenic patients

Antidepressive drugs reduce the mortality rate of schizophrenic patients, while treatment with bensodiazepines greatly increases it, especially as regards suicide. Giving several antipsychotics simultaneously, however, seems to have no effect at all. This according to a new study examining different drug combinations administered to patients with schizophrenia.

9 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Report: Nursing homes and anti-psychotic drugs

A report by the Boston Globe based on government information finds many nursing homes use powerful sedatives on patients who should not be getting them.

30 Apr 2012